Curi Capital purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, HoldingsChannel reports. The firm purchased 264 shares of the company’s stock, valued at approximately $44,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Eli Lilly and during the 4th quarter worth approximately $1,463,293,000. Price T Rowe Associates Inc. MD raised its position in Eli Lilly and by 51.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,094,613 shares of the company’s stock worth $2,042,017,000 after acquiring an additional 4,082,728 shares during the period. Avidity Partners Management LP acquired a new position in Eli Lilly and during the fourth quarter worth $136,845,000. Brandywine Global Investment Management LLC purchased a new position in Eli Lilly and during the fourth quarter valued at $132,324,000. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Eli Lilly and in the fourth quarter valued at about $92,322,000. 75.59% of the stock is owned by institutional investors.

In other news, major shareholder Lilly Endowment Inc sold 125,284 shares of the company’s stock in a transaction on Monday, March 8th. The stock was sold at an average price of $209.69, for a total value of $26,270,801.96. Following the transaction, the insider now owns 110,422,933 shares of the company’s stock, valued at approximately $23,154,584,820.77. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold 555,284 shares of company stock worth $106,132,302 in the last 90 days. Company insiders own 0.09% of the company’s stock.

Several research firms recently issued reports on LLY. Mizuho lifted their price objective on Eli Lilly and from $222.00 to $228.00 and gave the stock a “buy” rating in a report on Monday, February 1st. Barclays lifted their price target on Eli Lilly and from $190.00 to $232.00 and gave the stock an “overweight” rating in a research note on Monday, February 1st. Cowen increased their price objective on Eli Lilly and from $195.00 to $235.00 and gave the company an “outperform” rating in a research note on Friday, February 12th. Wolfe Research upgraded Eli Lilly and from a “peer perform” rating to an “outperform” rating and raised their price objective for the company from $147.00 to $183.00 in a report on Thursday, December 10th. Finally, Truist upped their target price on shares of Eli Lilly and from $200.00 to $215.00 in a report on Monday, February 1st. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Buy” and an average price target of $193.88.

Shares of LLY opened at $182.32 on Thursday. Eli Lilly and Company has a 12-month low of $129.21 and a 12-month high of $218.00. The firm has a market capitalization of $174.84 billion, a P/E ratio of 29.79, a P/E/G ratio of 1.57 and a beta of 0.37. The firm has a 50-day moving average price of $195.68 and a 200 day moving average price of $171.39. The company has a current ratio of 1.36, a quick ratio of 1.06 and a debt-to-equity ratio of 3.27.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Thursday, January 28th. The company reported $2.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.35 by $0.40. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The business had revenue of $7.44 billion during the quarter, compared to the consensus estimate of $7.27 billion. During the same quarter last year, the firm earned $1.73 EPS. The business’s revenue was up 21.7% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.